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Abstract
Prostate carcinoma is among the most common causes of cancer-related death in men,
representing 15% of all male malignancies in developed countries. Neuroendocrine differentiation
has been associated with tumor progression, poor prognosis and with the androgen-independent
status. Currently, no successful therapy exists for advanced, castration-resistant disease. Because
hypoxia has been linked to prostate cancer progression and unfavourable outcome, we sought to
determine whether hypoxia would impact the degree of neuroendocrine differentiation of prostate
cancer cells, in vitro.
Results—exposure of LNCaP cells to low oxygen tension induced a neuroendocrine phenotype,
associated with an increased expression of the transcription factor neurogenin3 and
neuroendocrine markers, such as neuron-specific enolase, chromogranin A and β3-tubulin.
Moreover, hypoxia triggered a significant decrease of Notch 1 and Notch 2 mRNA and protein
expression, with subsequent down regulation of Notch-mediated signalling, as demonstrated by
reduced levels of the Notch target genes, Hes1 and Hey1. Neuroendocrine differentiation was
promoted by attenuation of Hes1 transcription, as cells expressing a dominant negative form of
Hes1 displayed increased levels of neuroendocrine markers under normoxic conditions. Although
hypoxia down regulated Notch 1 and Notch 2 mRNA transcription and receptor activation also in
the androgen independent cell lines, PC3 and Du145, it did not change the extent of NE
differentiation in these cultures, suggesting that androgen sensitivity may be required for
transdifferentiation to occur.
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Conclusions—hypoxia induces neuroendocrine differentiation of LNCaP cells in vitro, which
appears to be driven by the inhibition of Notch signalling with subsequent down-regulation of
Hes1 transcription.
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INTRODUCTION
Carcinoma of the prostate is the second leading cause of cancer-related death in men,
representing 15% of all male malignancies in developed countries (1). Although the
incidence of prostate cancer varies according to race, about 85% of patients are diagnosed
after the age of 65 years (2). However, little is known about the molecular mechanisms that
underline its development and progression.
Neuroendocrine differentiation (NED) of prostate cancer leads to a worst prognosis and is
associated with a lack of response to androgen-deprivation therapy, which is the only
effective treatment for advanced metastatic disease. Indeed, it has been suggested that NE
differentiated prostate cancer cells present within the tumor mass sustain proliferation,
invasion and metastasis through the production and release of peptide hormones (3).
Moreover, NED has been associated with chemotherapy resistance (4).
NE cells exist in normal adult prostate, where they regulate growth, differentiation and
secretory properties of the gland. Malignant NE cells have been identified in all human
prostate cancer tissues, with a prevalence that varies among different studies (5, 6). This
may be due, at least in part, to inconsistency in techniques used for the identification of the
most widely employed markers of prostate NED, neuron-specific enolase (NSE) and
chromogranin A (CGA) (7).
How prostate cancer shifts towards the NE phenotype is still debated. Androgen deprivation
therapy seems to favour the appearance of NE cells through the activation of PI3K-AKT-
mTOR intracellular signalling pathway (8).
In a tumor mass, oxygen tension is constantly changing, following changes in microvascular
supply, with periods of acute and chronic hypoxic conditions (9). Hypoxia is involved in
cancer progression and has been linked to modulation of Notch signalling in solid tumors
(10, 11). Notch is an evolutionary conserved receptor/ligand system that mediates several
biological processes: cell fate specification, differentiation, proliferation, apoptosis,
migration, and angiogenesis (12, 13). Dysregulation of Notch signal occurs in several types
of tumors (14–16), including prostate cancer (17). Notch signalling is also required for
normal prostate development (18, 19). When Notch receptor interacts with its ligands, it
undergoes a series of proteolytic cleavages that result in the production of an intracellular
domain (NICD), which translocates to the nucleus where it binds to the transcription factor
CBF1 (13). The formation of the CBF1-NICD complex leads to the recruitment of the
nuclear protein MAML1 that functions as a transcriptional activator of CBF1-dependent
genes, such as transcriptional repressors belonging to the Hes and Hey families (20).
This study was aimed at investigating whether hypoxia influences the degree of NED of
prostate cancer cells, in vitro, and whether NE trans-differentiation is supported by Notch
signalling.
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Mouse monoclonal antibody against β3-tubulin (TUJ-1) (1:2500) and rabbit polyclonal
antibody against human Notch 1 (sc-6014-R) (1:1000) were obtained from Santa Cruz
Biotechnology Inc. (DBA, Italy); mouse monoclonal antibody against HIF- 1α (1:1000) was
obtained from Novus Biologicals (DBA, Italy); mouse monoclonal antibody against human
NSE (1:1500) was obtained from Dako Cytomation (Glostrup, Denmark); rabbit monoclonal
antibody against GAPDH (1:1000), mouse monoclonal antibody against HA epitope tag
(1:1000), and rabbit monoclonal antibody against human Notch 2 (D67C8) (1:1000) were
purchased from Cell Signaling Technology (Euroclone, Milan, Italy). Mouse monoclonal
antibody against V5 epitope tag (1:5000) was purchased from Invitrogen SRL (Milan, Italy).
Horseradish peroxidase (HRP)-conjugated secondary anti-mouse and anti-rabbit antibodies
were purchased from GE Healthcare Italia (Milan, Italy) and Pierce Biotechnology Inc.
(Euroclone, Milan, Italy), respectively. All other reagents were obtained from Sigma
(Sigma-Aldrich S.r.l., St. Louis, USA). The γ-secretase inhibitor DAPT (20 mM stock
solution) was dissolved in DMSO. Dihydrotestosterone (DHT) was dissolved in ethanol.
Cell cultures
LNCaP (androgen-dependent human prostate cancer cell line), PC-3 and Du145 (androgen-
independent human prostate cancer cell lines) were obtained from ATCC (Manassas, VA,
USA), maintained in liquid nitrogen and used within few weeks after thawing. Cells were
grown in RPMI-1640 (LNCaP) or DMEM (PC-3 and Du145) (Euroclone), supplemented
with 10% (vol/vol) fetal bovine serum (FBS) (Euroclone), L-glutamine (Euroclone) and 1%
(vol/vol) antibiotic/antimycotic solution (Gibco, Invitrogen S.r.l.). Hypoxia was achieved by
maintaining the cells at 2% oxygen, in a CO2 incubator (Forma Series II, Thermo Scientific)
with oxygen sensor control, and with CO2 and N2 gas regulators, for up to 14 days. The cells
were split every 4 days.
Cell growth analysis
To assess cell growth under normoxia and hypoxia, cultures were plated at 40.000 cells per
well, in a 6 well-tissue culture plate. At day three and five after plating, cells were detached
by trypsin and counted using a haemocytometer. Four wells were counted for each point.
Growth response to DHT stimulation was studied by plating 80.000 cells per well, in a 6
well-tissue culture plate. Forty-eight hours later, culture medium was changed with medium
containing 1% FBS and 4% charcoal-stripped FBS, and the cells were put in normoxic or
hypoxic environment. After five days, cells were stimulated with DHT [10 nM]; seven days
after treatment, cells were detached by trypsin and counted using a haemocytometer. Four
wells were counted for each point. Student’s t test was used for statistical analysis.
Phase contrast microscopy
Phase contrast photographs of the cells, under normoxic and hypoxic conditions were taken
with a phase contrast Zeiss Axiovert 25 inverted microscope, equipped with an AxioCam
MR camera and Axiovision software.
Immunocytochemistry
Mouse monoclonal antibody against NSE (pre-diluted) was obtained from CellMarque
(Ventana, Italy). The immunocytochemical analysis was performed by Benchmark XT
Ventana System. Cells, grown on poly-L-lysine treated glass slides, were rinsed with PBS,
and fixed in 50% ethanol. Immunostaining was performed using the HRP multimer system
and specific mouse monoclonal antibodies; the 3,3′-diaminobenzidine (DAB, Ventana) was
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used as a substrate chromogen solution for the development of the peroxidase activity
(UltraView Universal DAB Detection Kit. Ventana, Italy).
RNA extraction and quantitative Real Time RT-PCR
Total RNA was isolated using the RNEasy Mini Kit (Qiagen, Hilden, Germany), following
the manufacturer’s instructions. During RNA purification, the sample was treated with
Rnase-free Dnase I (Qiagen) to eliminate any genomic DNA contamination. The
concentration of total RNA was determined spectrophotometrically with Nanodrop®
ND-1000 (National Instruments Corporation, Texas, USA). Total RNA (1–2 μg) was
reverse transcribed into cDNA by using TaqMan reverse transcription reagents, with random
hexamers (Applied Biosystem Inc., Italy). The profile of the reverse transcription reaction
was 10 min at 25° C, 30 min at 48° C, and 5 min at 95° C. Each reverse transcription was
carried out in triplicate. Expression of Notch (N)1, N2, N3, N4, Jagged (J)1, J2, Delta-like
(Dll)-1, Dll-3, Dll-4, Hes1, Hey1, androgen receptor (AR), neurogenin (Ngn)3 and
chromogranin A (CGA) mRNA was determined by quantitative real-time polymerase chain
reaction RT-PCR (qPCR), performed using an ABI Prism 7900HT Sequence Detection
System (Applied Biosystems), according to the manufacturer’s instructions. All PCR
amplifications were performed using MicroAmp optical 96-well reaction plate with TaqMan
Fast Universal PCR Master Mix and with TaqMan Gene Expression Assay (Applied
Biosystems).
Adenoviral transduction
Dominant negative Hes1 (dnHes1:HA) (21), constitutively active Notch 1 (caN1:V5)
consisting of Notch 1 intracellular domain (22), and LacZ (control gene), cloned in a pAdlox
adenoviral construct, were used to transduce LNCaP cells. Recombinant adenoviruses were
produced, purified and titrated as described (23). Briefly, CRE8 cells were transfected with
SfiI-digested pAdlox-derived constructs, and infected with the ψ5 virus. Lysates were
prepared 4 days after infection. Viruses were passed twice through CRE8 cells, and purified
from the second passage using a caesium density gradient. The viruses were quantified by
optical density at 260 nm, and the bioactivity was determined by the plaque forming unit
assay. Adenoviral transduction was performed in serum-free DMEM with approximately
103 viral particles/cell in the presence of poly-D-lysine hydrobromide (Sigma Aldrich,
USA), for 2 hours at 37° C. Then the adenovirus-containing medium was removed and
replaced with serum-containing medium.
Western blot analysis
Cells grown under normoxic and hypoxic conditions were scraped in cold PBS, centrifuged
and resuspended in cold lysis buffer (10 mM TrisHCl pH7.4, 25 mM MgCl2, 1% Triton
X-100, 1 mM dithiothreitol, 0.1 mM phenylmethylsulfonyl fluoride, 10 μg/ml leupeptin, 2
μg/ml aprotinin, 1mM Na3VO4). Lysates were obtained by sonication on ice, followed by
centrifugation to collect supernatants. After measurement of total protein content (Comassie
Plus-Bradford Assay kit, Pierce), equal amounts of cell lysates (50 μg) were resolved by
10% (w/v) sodium dodecyl sulphate (SDS) – polyacrylamide gel electrophoresis (PAGE),
transferred to a nitrocellulose membrane (Hybond C, Amersham Pharmacia Biothec) and
immunoblotted using primary antibodies. Immunoreactive bands were visualized by
chemioluminescence assay (ECL) (Amersham Pharmacia Biotech), following
manufacturer’s instructions. Densitometric analysis was conducted using GAPDH
immunoreactive bands for normalization. Each experiment was performed at least three
times.
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LNCaP cells exposed to hypoxia adopt a neuroendocrine (NE) phenotype
LNCaP cells were exposed to 2% oxygen (hypoxia) for up to 14 days. Similar to other
reports (24), we found that transcription of HIF-1α mRNA was constitutive in LNCaP, and
was nearly unchanged after 24 hours of exposure to hypoxia (data not shown). However, the
expression of HIF-1α protein was enhanced under reduced oxygen tension, indicating
stabilization of the protein (25) (Figure 1A). Cells grown at 2% oxygen for at least three
days changed their morphology and assumed a neuronal-like phenotype, with the
appearance of long dendritic-like processes in numerous cells, suggesting NED. The
phenotypic change was more striking after seven days of hypoxia (Figure 1B) and still
evident at 14 days. To confirm that the change in phenotype was due to NED, we analyzed
the expression of two NE markers: neuron-specific enolase (NSE) (Figure 1C, 1D and 1F)
and class III beta (β3)-tubulin (26, 27) (Figure 1E and 1G): both markers were significantly
up-regulated after 7 days of exposure to hypoxia. Because neurogenin3 (Ngn3), a pro-
neurogenic bHLH transcription factor, was demonstrated to be expressed in the NE prostate
cancer mouse model, 12T-10 (28), we analyzed the expression of Ngn3 by qPCR, under
normoxic and hypoxic conditions. As demonstrated in Figure 1H, Ngn3 transcription was
significantly up-regulated by hypoxia. Neither PC-3 nor Du145 cells showed any change in
morphology suggestive of NED when grown under hypoxic conditions. According to this
observation, the level of expression of NED markers did not rise when the cells were
exposed to reduced oxygen tension (data not shown).
Hypoxia modulates the expression of Notch receptors and ligands
Because Notch signalling has a key role in cell fate and differentiation, and hypoxia has
been demonstrated to modulate Notch signalling in some tumors (10), we sought to
determine whether Notch was involved in the hypoxia-mediated NED of LNCaP cells.
Notch 1–4 (N1-4), Jagged 1 (J1) and J2, Delta-like (Dll)-1, 3 and 4 mRNA levels were
assessed by qPCR, under normoxic and hypoxic conditions. N4 and Dll-3 were undetectable
under both conditions. N1 and N2 mRNA were abundant under normoxia and decreased
significantly under hypoxia (Figure 2A). N3 mRNA was less represented and slightly
decreased under hypoxic conditions (Supplementary Figure 1A). We also determined the
expression of N1 and N2 proteins by Western blotting. As shown in Figure 2C, compared to
normoxia (lane 1), the expression of the transmembrane (TM) form of N1 was undetectable
and TM N2 was significantly reduced under hypoxia (lane 2). The decrease of N1 and N2
receptor proteins was not modified by treatment of the cells with γ-secretase inhibitor
DAPT (lane 3), indicating that it was related to reduced protein translation, rather than
receptor activation. The decreased expression of Notch receptors was maintained up to 14
days (data not shown). J1 and J2 were the main Notch ligands expressed in LNCaP; J1, J2,
Dll-1 and Dll-4 mRNA levels decreased significantly under hypoxic conditions (Figure 2B).
Similarly to Notch receptors, hypoxia-induced modification of ligand expression was still
maintained after 14 days of exposure to hypoxic conditions (data not shown). In order to
determine whether the modulation of Notch receptor/ligand system under hypoxia was a
common feature of prostate cancer cells, we examined PC-3 and Du145 for the transcription
levels of Notch 1–4 and their ligands, under normoxic and hypoxic conditions: PC-3 and
Du145 expressed abundant levels of N1, N2 and N3; J1 and J2 were the main ligands
(Supplementary Figure 1B). N4 and Dll-3 were undetectable. Under hypoxia, N1 and N2
were significantly down regulated in both cell lines (Supplementary Figure 2A). With the
exception of J2 in PC-3 cells, ligands were also significantly down regulated under hypoxic
conditions (Supplementary Figure 2B).
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Hypoxia modulates Notch-mediated signalling
We next studied Notch signalling under normoxic and hypoxic conditions and found that the
transcription of Notch target genes, Hes1 and Hey1, was significantly down-regulated when
LNCaP cells were exposed to 2% oxygen, in comparison to normoxia, indicating that Notch-
mediated signalling was turned down. Cells treated with the γ-secretase inhibitor DAPT
were used as controls for inhibition of Notch activation (Figure 2D). As in LNCaP cells,
Hes1 and Hey1 expression was significantly down regulated when PC-3 and Du145 were
grown at 2% oxygen (Supplementary Figure 3).
Notch signalling modulates the extent of NED in LNCaP cells
Because Notch signalling was down regulated under hypoxia and because in the developing
neuroblast, Notch signalling and transcription of Hes genes are repressed (29), we sought to
determine whether hypoxia-mediated NED was supported by the down-regulation of Notch
signal. To do so, we transduced LNCaP cells with a dominant negative form of Hes1
(dnHes1) (21). Cells transduced with LacZ were used as controls. Ninety-six hours after
infection, the cells were analyzed for the pro-neurogenic transcription factor Ngn3 and
chromogranin A (CGA) mRNA expression, using qPCR (Figure 3A and 3B), and for NSE
and β3-tubulin protein expression, by Western blotting (Figure 3C). Cells expressing
dnHes1 up-regulated Ngn3, CGA, NSE andβ3-tubulin, compared to cells infected with the
LacZ construct. These data suggest that hypoxia-induced NED may be facilitated by the
attenuation of Notch receptor activity, through the down-regulation of Hes1 transcription.
To confirm that the extent of NE features correlated to the level of Notch receptor
activation, we next transduced LNCaP cells with a construct expressing a constitutively
active form of Notch 1 (caN1) (22). Cells transduced with LacZ were used as controls.
Ninety-six hours after infection, we analyzed the level of NE markers: GCA by qPCR
(Figure 3D), and NSE and β3-tubulin by Western blotting (Figure 3E). In cells virally
transduced with caN1, the expression of all three NE markers was significantly reduced.
Hypoxia modulates the expression and function of androgen receptor (AR)
Because it has been reported that malignant prostatic NE cells are androgen-independent
(30), we analyzed the growth of the cells and the expression of AR mRNA by qPCR, under
normoxic and hypoxic conditions. As demonstrated in Figure 4A, cell growth was not
inhibited under hypoxia, but rather enhanced. However, transcription of AR significantly
decreased when LNCaP cells were exposed to reduced oxygen tension (Figure 4B).
Moreover, stimulation of the cells with 5α-dihydrotestosterone (DHT) for 7 days was able
to sustain cell growth under normoxia, but not under hypoxic conditions (Figure 4C),
indicating that at 2% oxygen cells were unresponsive to exogenous hormone stimulation. To
test whether there was a correlation between the expression of AR and the level of Notch
signal, we analyzed cells transduced with caN1 and dnHes1 for AR mRNA expression, by
qPCR. Cells transduced with LacZ were used as controls. As reported in Figure 4D, caN1
potentiated, while dnHes1 attenuated, the transcription of the receptor. These data suggest
that down regulation of Notch signal may contribute to the down regulation of AR when the
cells are grown under reduced oxygen tension.
DISCUSSION
Progression of prostate cancer to a hormone-independent state is associated with resistance
to androgen-deprivation therapy and poor prognosis. A growing body of evidence suggests
that NED plays a role in the development of androgen-independency. Moreover, a recent
report demonstrated that focal NED in prostate cancer is a powerful independent predictor of
outcome (31). NED can range from the presence of scattered clusters of neuronal-like cells
within the adenocarcinoma tumor mass, to a small cell carcinoma or carcinoid of the
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prostate, which is composed of 100% NE cells (32, 33). A recent report showed that a
xenograft of NE differentiated prostate cancer cells implanted into a castrated mouse,
enabled the growth of a xenograft of androgen-dependent tumor cells implanted into the
opposing flank. This result suggests that NE differentiated cells, within the tumor mass, may
support the growth of androgen-dependent cancer cells, even in the absence of androgenic
stimulation (3), likely favouring the selection of hormone-independent clones. For this
reason, understanding the molecular mechanisms that underline NE transdifferentiation
should be of great interest.
Like many solid tumors, hypoxia develops in prostate cancerous tissues and has a role in
tumor development and progression (34). We demonstrated that exposure of LNCaP cells to
hypoxia induced NED. In a tumor mass, changes in microvascular supply lead to the
development of acute and chronic hypoxic conditions (9). Pathological hypoxia has been
established under 5% oxygen; however, compromised blood flow in specific areas may
result in oxygen tension less than 1% (35). We chose to grow the cells at 2% oxygen to be
able to study the “long term”, chronic effect of oxygen reduction. Exposure of LNCaP cells
to hypoxia induced a profound modification of Notch receptor-ligand expression profile.
Notch signalling is central in cell fate specification, in embryonic and adult tissues (12, 13).
Notch mediated signal has been linked increasingly to carcinogenesis; however, its role in
cancer is highly context-dependent. In lung and breast cancer, hypoxia appears to increase
Notch signaling (10, 11); in breast cancer cells hypoxia up regulates the expression of Notch
receptors and ligands, as well as of Notch target genes, Hes1 and Hey1 (11). In LNCaP
cells, low oxygen tension produced the opposite effect on Notch expression and activity,
suggesting a further tissue-specific regulation of the Notch system. Hypoxia down regulated
N1 and N2 mRNA transcription also in the androgen independent cell lines, PC-3 and
Du145, although it did not change the extent of NE trans-differentiation in these models. It
is possible that androgen sensitivity may be required for trans-differentiation to occur, as
demonstrated by a number of studies that pointed out how NED progresses more rapidly if
androgen deprivation is more intense (36, 37).
Moreover, as suggested by Marchiani (38), there is variability in the pathways leading to
NED among different cell lines, in vitro, which may mirror tumor variability of prostate
cancer cells, in vivo.
Notch is a major regulator of neuronal development, through the well-known mechanism of
lateral inhibition: in a cell differentiating towards the neuronal lineage, Notch is not
activated and, consequently, transcription of Hes genes is repressed; the cell expresses the
transcription factor Ngn, which leads to the expression of Notch ligands. The expression of
ligands on the developing neuroblast activates Notch receptors on adjacent cells, leading to
the transcription of Hes genes that function as repressors of neuronal differentiation (39).
This mechanism prevents the cells surrounding the newly formed neuroblast to differentiate
towards the neuronal lineage as well. Hes1 has been demonstrated to be expressed by almost
all undifferentiated cells, and it is crucial for suppressing differentiation of neural stem cells.
Interestingly, Hes1 deficient mice exhibit premature differentiation and severe defects in the
brain, eye and pancreas (39). Recently, several reports have suggested the involvement of
Notch signalling in pancreatic exocrine and endocrine cell fate, through a mechanism similar
to lateral inhibition: in the developing pancreas, a cell committed to the endocrine lineage
expresses Ngn3, forcing neighbouring cells to adopt a non-endocrine phenotype. The
existence of a cross-talk between Ngn and Hes transcription factors in the developing
pancreas has been demonstrated by several lines of evidence: overexpression of Ngn3 or
disruption of Hes1 gene results in an increased number of endocrine progenitor cells, with
depletion of precursors bearing the capacity to differentiate into exocrine pancreas (40, 41).
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It has been demonstrated that Hes1 is able to halt Ngn3 expression by binding to several
silencer sites near the transcription initiation site of the gene (40).
We report that, under hypoxic conditions, LNCaP cells down regulate Notch signal and
Hes1 mRNA transcription, and up-regulate the expression of Ngn3 and the extent of NE
features. Because a dominant negative Hes1 construct is also able to increase the level of
Ngn3 transcription and NED, we propose that the loss of Notch signalling may determine
NED in a manner similar to what has been described during pancreas development, with
down regulation of Hes1 allowing neuronal associated proteins to be synthesized. In a
previous study, immunohistochemical analysis of 12T-10 transgenic NE prostate cancer
mouse model demonstrated the presence of pro-neuronal transcription factors, such as
Foxa2, Ngn3 and Nkx2.2, associated with a loss of Hes1 transcript (28). Moreover, in 80
samples of human prostate cancers, grouped according to the level of CGA expression,
human achaete-scute homolog 1 (hASH1), which is negatively regulated by Notch signal,
was expressed and co-localized with CGA, in NE differentiated samples, and its expression
correlated positively to the extension of NE features (42). In addition, during the preparation
of this manuscript, a paper was published reporting that the formation of NE prostate tumors
in the TRAMP mouse model is regulated by HIF-1α availability. The authors also
demonstrated that HIF-1α cooperates with the pro-neuronal transcription factor Foxa2 to
initiate the transcriptional program required for the NE phenotype to develop (43). Our data
confirm that hypoxia can trigger the appearance of NED in prostate cancer cells and suggest
a further level of complexity, with modulation of Notch signalling as an additional
contributor. Interestingly, using osteoblastic skeletal prostate metastatic cancer cells,
Zayzafoon and colleagues demonstrated that expression of N1 and Hes1 was increased,
when compared to the primary tumor, indicating that Notch signalling was activated, and
likely participated to the acquisition of osteoblastic properties (44). Therefore, modulation of
Notch signalling appears to be crucial for prostate cancer progression by determining cancer
cell differentiation and controlling the acquisition of specific phenotypes.
Several reports have indicated that malignant prostatic NE cells are AR negative (30). When
LNCaP cells were grown under hypoxic conditions, AR mRNA transcription was
significantly down-regulated, although not completely absent. We also found that the level
of AR transcription correlated to the level of Notch signal. Therefore, we propose that the
attenuation of Notch mediated signal, detected under hypoxia, promotes not only NED but
also a reduction of AR expression.
Some authors have reported an increased sensitivity of prostate cancer cells to hormone
stimulation, under hypoxia (45). When we assessed cell growth in our experimental system,
we found that LNCaP cells exposed to hypoxia were able to grow even faster than cells
exposed to normoxia. At the same time, at 2% oxygen, the cells did not respond to androgen
stimulation. These results are in accordance with Suzuki et al. that reported that DHT-
dependent growth and ARE-mediated transcriptional activity of LNCaP cells were
depressed under reduced oxygen tension (46). Although this behavior seems to suggest the
acquisition of an androgen-independent phenotype, when we passaged the cells with
charcoal-stripped serum, which is considered a model of androgen-deprivation, their growth
was hampered equally under normoxia and hypoxia (data not shown). One possible
explanation is that charcoal-stripped serum is deprived not only of androgens, but also of
other mitogens that may be necessary to sustain the growth of prostate cancer cells, under
hypoxia, in our experimental system. Further studies will be necessary to establish whether
chronic hypoxia favors the appearance of an androgen-independent phenotype and to
elucidate which mitogenic stimuli sustain the growth of the cells under reduced oxygen
tension. One likely candidate is the prototype member of the Fibroblast Growth Factor
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family, FGF-1. Indeed FGF-1 is a well-known mitogenic stimulus for prostate cancer cells
(47) and its secretion has been linked to a down regulation of N1 receptor activity (48).
Several lines of evidence indicate that Notch signalling may have a facilitating role in the
progression of prostate cancer; indeed, J1 is highly expressed in metastatic tumors and in
clinically localized tumors with higher risk of recurrence (49). Moreover, down regulation
of N1 and J1 inhibits cancer cell growth, migration and invasion (50, 51). For all these
reasons, strategies aimed at inhibiting Notch pathway have been proposed as alternative
anti-cancer therapies for metastatic prostate cancer, refractory to endocrine therapy, whose
treatment is currently based on docetaxel (52). However, based on our results, great caution
should be exerted before proposing such strategy as single therapy in patients with advanced
prostate cancer, as it may favour the appearance of a NE-mediated, hormone-independent
phenotype with self-sustained proliferative capacity and aggressive clinical behaviour. At
the same time, characterizing the down-regulation of Notch signal as a mechanism involved
in NED may open new perspectives for treatment of hormone-refractory tumors. Indeed,
while somatostatin analogs have been employed with quite elusive results in prostate
cancers characterized by NE features (53), Notch signalling may be regarded as a novel
molecular target to prevent/revert NE transdifferentiation.
In conclusion, hypoxia induces down regulation of Notch-mediated signal, sustaining NED
of prostate cancer cells in vitro. Further studies are needed to understand whether the
modulation of Notch, in combination with strategies aimed at inhibiting signalling pathways
responsible for the self-sustained proliferative capacity (54), may slow down the progression
of prostate cancer toward a NE-mediated, androgen-independent phenotype.
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A. Western blotting for the detection of HIF-1α in LNCaP cells exposed to normoxia (N) or
hypoxia (H) for 24 hours. Detection of GAPDH was used for normalization of protein
loading; B–C. LNCaP cells exposed to hypoxia (H) for 7 days, compared to cells exposed to
normoxia (N), assessed by phase contrast microscopy (B) and by immunoperoxidase
staining (brown) for the detection of NSE (C); D–E. Representative immunoblot for the
expression of NSE (D) and β3-tubulin (E) in LNCaP cells exposed to normoxia (N) and
hypoxia (H) for 7 days. Detection of GAPDH was used for normalization of protein loading.
F–G. Densitometric analysis of three independent experiments for the detection of NSE (F)
and β3-tubulin (G); values are expressed as mean ± SE. H. Neurogenin (Ngn)3 mRNA
expression in LNCaP cells exposed to normoxia (N) and hypoxia (H), at different time
points, assessed by quantitative real time PCR.
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A–B. Notch 1 (N1), N2, Jagged (J)1, J2, Delta-like (Dll)-1, Dll-4 mRNA expression in
LNCaP cells exposed to normoxia and hypoxia for 7 days, assessed by quantitative real time
PCR. Data are expressed as fold expression of mRNA levels under hypoxia, normalized to
normoxia level (equal 1). C. Western blotting for the detection of transmembrane N1 and
N2 proteins in LNCaP cells exposed to normoxia (1), hypoxia (2) and hypoxia + DAPT [20
μM] (3), for 7 days. D. Expression of Notch target genes, Hes1 and Hey1, mRNA in LNCaP
cells exposed to normoxia and hypoxia for 7 days, assessed by quantitative real time PCR.
Cells treated with the γ-secretase inhibitor DAPT [20 μM] were used as control for
inhibition of Notch signal.
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A–C. LNCaP cells virally transduced with LacZ or with a dominant negative form of Hes1
(dnHes1), in frame with a HA-tag, were analyzed for Ngn3 and CGA mRNA expression 4
days after transduction, by quantitative real time PCR (A–B) and for NSE and β3-tubulin
protein expression, by Western blotting (C). Detection of HA-tag was used to determine the
expression of the transduced dnHes1 construct. Detection of GAPDH was used for
normalization of protein loading. D–E. LNCaP cells virally transduced with LacZ or with a
constitutively active form of N1 (caN1), in frame with a V5-tag, were analyzed for CGA
mRNA expression 3 days after transduction, by quantitative real time PCR (D), and for NSE
and β3-tubulin protein expression, by Western blotting (E). Detection of V5-tag was used to
determine the expression of the transduced caN1 construct. Detection of GAPDH was used
for normalization of protein loading.
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A. Exponential growth curve of LNCaP cells grown under normoxic and hypoxic
conditions; B. AR mRNA expression in LNCaP cells exposed to normoxia (N) and hypoxia
(H) for 7 days, assessed by quantitative real time PCR; C. Growth of LNCaP cells under
normoxic (N) and hypoxic (H) conditions, in the absence or presence of DHT [10 nM]. Cells
were counted at day 7. Data are shown as mean ± standard deviation; D. Expression of AR
mRNA in LNCaP cells virally transduced with LacZ, caN1 and dnHES1, 4 days after
transduction, assessed by quantitative real time PCR.
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